LUNSUMIO

mosunetuzumab · Genentech, Inc.

Drug timelines are a Plus or Pro feature.

17 regulatory and trial events tracked for LUNSUMIO, covering 2022-12-22 to 2026-07-02. Get the full timeline:

Most recent: EMA Authorised: Lunsumio (mosunetuzumab) — Roche Registration GmbH